This article outlines the principal challenges to establish a standard phase-2 approach for progressive multiple sclerosis (PMS) and presents referring strategies to accelerate the registration process via a guidance approved by regulatory agencies. Accordingly, the contribution of ‘big datasets’ for a better understanding of the natural history of primary-progressive multiple sclerosis (PPMS) and secondary-progressive multiple sclerosis (SPMS) and of their prognostic factors and the value of novel biomarkers are discussed. The establishment of new industry–academic initiatives, such as independent consortia under the umbrella of Progressive MS Alliance (PMSA), with the endorsement of MS organizations and Scientific Societies (e.g. European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)) may be crucial to overcome some of the current challenges. Within this frame, the continuous interaction with regulatory agencies is instrumental for the formal validation of the many developments suitable to improve clinical trialling in PMS.
BartekRJ. Foundation-industry relationships – a new business model joint-venture philanthropy in therapy development. Curr Top Med Chem2014; 14: 313–318.
4.
Butlen-DucuingFPétavyFGuizzaroL. Regulatory watch: Challenges in drug development for central nervous system disorders: A European Medicines Agency perspective. Nat Rev Drug Discov2016; 15: 813–814.
5.
SalvettiMLandsmanDSchwarz-LamP. Progressive MS: From pathophysiology to drug discovery. Mult Scler2015; 21: 1376–1384.
6.
ComiG. Disease-modifying treatments for progressive multiple sclerosis. Mult Scler2013; 19: 1428–1436.
7.
ThompsonAJ. A much-needed focus on progression in multiple sclerosis. Lancet Neurol2015; 14: 133–135.
OntanedaDFoxRJChatawayJ. Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives. Lancet Neurol2015; 14: 208–222.
11.
HawkerKOConnorPFreedmanMS. Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol2009; 66: 460–471.
12.
LublinFMillerDHFreedmanMS. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): A phase 3, randomised, double-blind, placebo-controlled trial. Lancet2016; 387: 1075–1084.
13.
ChatawayJNicholasRToddS. A novel adaptive design strategy increases the efficiency of clinical trials in secondary progressive multiple sclerosis. Mult Scler2011; 17: 81–88.
BarkhofFHulstHEDrulovicJ. Ibudilast in relapsing-remitting multiple sclerosis: A neuroprotectant?Neurology2010; 74: 1033–1040.
16.
ConfavreuxC1VukusicSAdeleineP. Early clinical predictors and progression of irreversible disability in multiple sclerosis: An amnesic process. Brain2003; 126(Pt4): 770–782.
17.
LerayEYaouanqJLePageE. Evidence for a two-stage disability progression in multiple sclerosis. Brain2010; 133: 1900–1913.
18.
TremlettHYousefiMDevonshireV. Impact of multiple sclerosis relapses on progression diminishes with time. Neurology2009; 73: 1616–1623.
19.
ScalfariANeuhausADegenhardtA. The natural history of multiple sclerosis, a geographically based study 10: Relapses and long-term disability. Brain2010; 133: 1914–1929.
20.
LublinFDReingoldSCCohenJA. Defining the clinical course of multiple sclerosis: The 2013 revisions. Neurology2014; 83(3): 278–286.
21.
TrojanoMTintoreMMontalbanX. Treatment decisions in multiple sclerosis – insights from real-world observational studies. Nat Rev Neurol2017; 13(2): 105–118.
22.
RosenbaumPRRubinDB. The central role of the propensity score in observational studies for causal effects. Biometrika1983; 70(1): 41–55.
23.
KarimMEGustafsonPPetkauJ. Marginal structural Cox models for estimating the association between β-interferon exposure and disease progression in a multiple sclerosis cohort. Am J Epidemiol2014; 180(2): 160–171.
24.
CookJACollinsGS. The rise of big clinical databases. Br J Surg2015; 102(2): e93–e101.
25.
SormaniMPEvangelouN. New imaging language skills required in MS. Neurology2015; 85(13): 1096–1097.
26.
KalincikTKuhleJPucciE. Data quality evaluation for observational multiple sclerosis registries. Mult Scler2017; 23(5): 647–655.
27.
BeboBFFoxRJLeeJ. Landscape of MS patient cohorts and registries: Recommendations for maximizing impact. Mult Scler. Epub ahead of print 1March2017. DOI: 10.1177/1352458517698250.
28.
LizakNLugaresiAAlroughaniR. Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis. J Neurol Neurosurg Psychiatry2017; 88(3): 196–203.
SignoriAIzquierdoGLugaresiA. Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis. Mult Scler. Epub ahead of print 1April2017. DOI: 10.1177/1352458517703800.
31.
Paz SoldánMMNovotnaMAbou ZeidN. Relapses and disability accumulation in progressive multiple sclerosis. Neurology2015; 84(1): 81–88.
32.
KochMWGreenfieldJJavizianO. The natural history of early versus late disability accumulation in primary progressive MS. J Neurol Neurosurg Psychiatry2015; 86(6): 615–621.
33.
MontalbanXBelachewSWolinskyJS. Ocrelizumab in primary progressive and relapsing multiple sclerosis. N Engl J Med2017; 376(17): 1694.
34.
ZaratinPComiGCoetzeeT. Progressive MS alliance industry forum: Maximizing collective impact to enable drug development. Trends Pharmacol Sci2016; 37: 808–810.
35.
FoxRJThompsonABakerD. Setting a research agenda for progressive multiple sclerosis: the International Collaborative on Progressive MS. Mult Scler2012; 18: 1534–1540.
ZhangJWaubantECutterG. Composite end points to assess delay of disability progression by MS treatments. Mult Scler2014; 20(11): 1494–1501.
39.
KuhleJBarroCDisantoG. Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity. Mult Scler2016; 22(12): 1550–1559.
40.
Novartis CAR-T cell therapy CTL019 receives FDA Breakthrough Therapy designation for treatment of adult patients with r/r DLBCL. Basel: Novartis, 2017.
